Physician profile
Karina Hasing
NPI 1083002513
$1,360.31
in general payments reported to CMS, 2019-2025
16 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $124 · 2023: $211 · 2024: $523 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.26 |
| Education | $132.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $282.57 | 2022-2025 | Tremfya |
| Abbvie INC. | $169.69 | 2024-2025 | |
| Pfizer INC. | $146.49 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $146.17 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $128.83 | 2022-2025 | Ebglyss, Taltz |
| Janssen Scientific Affairs, LLC | $124.52 | 2021 | |
| Incyte Corporation | $79.09 | 2022-2024 | Opzelura |
| Amgen INC. | $56.88 | 2023 | Otezla |
| Galderma Laboratories, L.P. | $49.27 | 2021-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $39.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $36.87 | 2021 | |
| Organogenesis INC. | $33.23 | 2024 | |
| Ucb, INC. | $25.33 | 2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $14.51 | 2024 | Zoryve |
| Genzyme Corporation | $14.50 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Hasing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.